| Year |
Citation |
Score |
| 2019 |
Morrison-Smith CD, DiBona A, Walsh E, Danga K, Filic I, Knox T, Grayson A, Cameron M, French C. Abstract B014: Novel dual BET/p300 bromodomain inhibitors therapeutically inhibit BRD4-NUT driven NUT Carcinomas Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B014 |
0.445 |
|
| 2017 |
Alekseyenko AA, Walsh EM, Zee BM, Pakozdi T, Hsi P, Lemieux ME, Dal Cin P, Ince TA, Kharchenko PV, Kuroda MI, French CA. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 28484033 DOI: 10.1073/Pnas.1702086114 |
0.391 |
|
| 2016 |
Kuroda MI, Alekseyenko AA, Walsh EM, Wang X, Grayson A, Hsi PT, Kharchenko PV, French CA. Abstract 2655: Oncogenic chromatin factors drive cell type-specific transcription within megadomains in NUT midline carcinoma Cancer Research. 76: 2655-2655. DOI: 10.1158/1538-7445.Am2016-2655 |
0.475 |
|
| 2015 |
Alekseyenko AA, Walsh EM, Wang X, Grayson AR, Hsi PT, Kharchenko PV, Kuroda MI, French CA. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes & Development. 29: 1507-23. PMID 26220994 DOI: 10.1101/Gad.267583.115 |
0.431 |
|
| 2015 |
Walsh EM, Niu M, Bergholz J, Xiao ZX. Nutlin-3 down-regulates retinoblastoma protein expression and inhibits muscle cell differentiation. Biochemical and Biophysical Research Communications. 461: 293-9. PMID 25871794 DOI: 10.1016/J.Bbrc.2015.04.024 |
0.401 |
|
| 2014 |
Wu J, Liang S, Bergholz J, He H, Walsh EM, Zhang Y, Xiao ZX. ΔNp63α activates CD82 metastasis suppressor to inhibit cancer cell invasion Cell Death and Disease. 5. PMID 24901051 DOI: 10.1038/cddis.2014.239 |
0.32 |
|
| 2014 |
French CA, Rahman S, Walsh EM, Kühnle S, Grayson AR, Lemieux ME, Grunfeld N, Rubin BP, Antonescu CR, Zhang S, Venkatramani R, Dal Cin P, Howley PM. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discovery. 4: 928-41. PMID 24875858 DOI: 10.1158/2159-8290.Cd-14-0014 |
0.45 |
|
| 2014 |
Grayson AR, Walsh EM, Cameron MJ, Godec J, Ashworth T, Ambrose JM, Aserlind AB, Wang H, Evan GI, Kluk MJ, Bradner JE, Aster JC, French CA. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma Oncogene. 33: 1736-1742. PMID 23604113 DOI: 10.1038/Onc.2013.126 |
0.471 |
|
| 2014 |
Bergholz J, Zhang Y, Wu J, Meng L, Walsh EM, Rai A, Sherman MY, Jim Xiao ZX. ΔNp63α regulates Erk signaling via MKP3 to inhibit cancer metastasis Oncogene. 33: 212-224. PMID 23246965 DOI: 10.1038/Onc.2012.564 |
0.395 |
|
| 2014 |
Walsh E, Kuhnle S, Rahman S, Lemieux M, Howley P, French C. Abstract 2476: A novel NUT translocation partner binds to BRD4 and is necessary for the blockade of differentiation in NUT midline carcinoma Cancer Research. 74: 2476-2476. DOI: 10.1158/1538-7445.Am2014-2476 |
0.447 |
|
| 2013 |
Walsh EM, Grayson AR, Cameron MJ, Godec J, Ashworth T, Aserlind AB, Wang H, Evan G, Kluk MJ, Bradner JE, Aster JC, French CA. Abstract B39: MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-B39 |
0.475 |
|
| 2009 |
Du W, Wu J, Walsh EM, Zhang Y, Chen CY, Xiao ZX. Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3. The Journal of Biological Chemistry. 284: 26315-21. PMID 19648117 DOI: 10.1074/Jbc.M109.046904 |
0.415 |
|
| 2008 |
Qiu W, Wu J, Walsh EM, Zhang Y, Chen CY, Fujita J, Xiao ZXJ. Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells Oncogene. 27: 4034-4043. PMID 18332869 DOI: 10.1038/Onc.2008.43 |
0.393 |
|
| Show low-probability matches. |